News

Phase 1 trial of cell therapy seeks more Parkinson’s patients

A small Phase 1 clinical trial testing a treatment approach that uses stem cells derived from a patient’s blood cells to replace the dopamine-producing neurons progressively lost in Parkinson’s disease is looking for three more patients. The first-of-its-kind Phase 1 study (NCT06422208), being conducted at Harvard Medical School’s…

First patient dosed in Parkinson’s clinical trial of Ventus’ VENT-02

A Phase 2a clinical trial testing Ventus Therapeutics’ VENT-02 — a novel brain-penetrating oral medication — in adults with mild to moderate Parkinson’s disease has dosed its first patient. The study (NCT06822517), expected to enroll about 30 people with Parkinson’s, is assessing the treatment’s safety, tolerability, effects on…

FDA lists platform using rhythm to aid walking as Class II device

Note: This story was updated March 13, 2025, to correct that the company’s proprietary software is not available as a downloadable smartphone app. The U.S. Food and Drug Administration (FDA) has listed MR-005, MedRhythms’ digital therapeutic platform using rhythmic beats to help with walking in…

Celon’s small molecule eases levodopa-induced dyskinesia

A daily dose of CPL’36, an oral small molecule in the pipeline of Celon Pharma, may ease symptoms for patients who experience levodopa-induced dyskinesia, or uncontrolled movements as a side effect of the mainstay Parkinson’s disease treatment, within one week. That’s according to data from a Phase 2 clinical…

StrivePD Guardian launched to better personalized Parkinson’s care

Rune Labs has launched StrivePD Guardian, a personalized care delivery service to help Parkinson’s disease patients manage their condition more effectively by combining expert coaching with artificial intelligence (AI)-driven health monitoring. The program pairs the StrivePD mobile app with an Apple watch, offering users continuous monitoring of…

Onward Medical using 2 grants to test spinal stimulation device

Onward Medical has received two grants totaling about $2.5 million to support early feasibility studies assessing whether its implantable spinal stimulation system, called ARC-IM, can lessen mobility difficulties and blood pressure instability in people with Parkinson’s disease. The ARC-IM system — in which targeted stimulation can…

Trial volunteer awards go to Parkinson’s, Alzheimer’s patients

A research advocate diagnosed with Parkinson’s disease and a former nurse with Alzheimer’s disease were among recipients of volunteer awards from the Global Alzheimer’s Platform Foundation (GAP). GAP’s Citizen Scientist Awards acknowledge the contributions of volunteers in clinical trials for neurodegenerative diseases. Each year, GAP’s network of research…